{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:14:29Z","timestamp":1788405269349,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd013550.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000}}],"reference-count":78,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013550.pub3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:23:47Z","timestamp":1779186227000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical immunosuppressants for blepharitis in adults"],"prefix":"10.1002","volume":"2026","author":[{"given":"Ka Wai","family":"Kam","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences; Prince of Wales Hospital, The Chinese University of Hong Kong; Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Mehraban Far","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Manitoba; Winnipeg, Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz Wing","family":"Yim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine; University of Colorado Anschutz; Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Jia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences; Prince of Wales Hospital, The Chinese University of Hong Kong; Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Yue","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences; Prince of Wales Hospital, The Chinese University of Hong Kong; Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-3218","authenticated-orcid":false,"given":"Alvin L.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences; Prince of Wales Hospital, The Chinese University of Hong Kong; Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"supported by the Cochrane Eyes and Vision Review Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"10.1002\/14651858.CD013550.pub3-BIB0001|cit1","unstructured":"Blepharitis PPP - 2018 www.aao.org\/preferred-practice-pattern\/blepharitis-ppp-2018"},{"issue":"4","key":"10.1002\/14651858.CD013550.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"P50","DOI":"10.1016\/j.ophtha.2023.12.036","article-title":"Blepharitis preferred practice pattern\u00ae","volume":"131","author":"Lin","year":"2024","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD013550.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","article-title":"The International Workshop on Meibomian Gland Dysfunction: report of the Definition and Classification subcommittee","volume":"52","author":"Nelson","year":"2011","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD013550.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","article-title":"The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction","volume":"52","author":"Geerling","year":"2011","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD013550.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jtos.2014.12.002","article-title":"Meibomian glands and ocular surface inflammation","volume":"13","author":"Suzuki","year":"2015","journal-title":"Ocular Surface"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013550.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1542-0124(12)70620-1","article-title":"Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment","volume":"7","author":"Lemp","year":"2009","journal-title":"Ocular Surface"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.12809\/hkjo-v22n1p18-21","article-title":"Prevalence of eyelid diseases among adults in Hong Kong","volume":"22","author":"Mak","year":"2018","journal-title":"Hong Kong Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD013550.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/ceo.12929","article-title":"Ten-year incidence and prevalence of clinically diagnosed blepharitis in South Korea: a nationwide population-based cohort study","volume":"45","author":"Rim","year":"2017","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD013550.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/ICO.0000000000001208","article-title":"Estimation of prevalence of meibomian gland dysfunction in Japan","volume":"36","author":"Amano","year":"2017","journal-title":"Cornea"},{"issue":"13","key":"10.1002\/14651858.CD013550.pub3-BIB0010|cit10","first-page":"774","article-title":"Chronic blepharitis: treatment patterns and prevalence","volume":"44","author":"Venturino","year":"2003","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD013550.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00003226-200009000-00010","article-title":"Changing concepts in the diagnosis and management of blepharitis","volume":"19","author":"McCulley","year":"2000","journal-title":"Cornea"},{"issue":"8","key":"10.1002\/14651858.CD013550.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/bjo.68.8.524","article-title":"Comparative bacteriology of chronic blepharitis","volume":"68","author":"Dougherty","year":"1984","journal-title":"British Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD013550.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10384-018-0624-3","article-title":"Occurrence of demodex species in patients with blepharitis and in healthy individuals: a 10-year observational study","volume":"62","author":"Biernat","year":"2018","journal-title":"Japanese Journal of Ophthalmology"},{"issue":"Pt 3","key":"10.1002\/14651858.CD013550.pub3-BIB0014|cit14","first-page":"314","article-title":"Bacterial aspects of chronic blepharitis","volume":"105","author":"McCulley","year":"1986","journal-title":"Transactions of the Ophthalmological Societies of the United Kingdom"},{"issue":"7","key":"10.1002\/14651858.CD013550.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/ICO.0000000000000452","article-title":"Eyelid tattooing induces meibomian gland loss and tear film instability","volume":"34","author":"Lee","year":"2015","journal-title":"Cornea"},{"issue":"6","key":"10.1002\/14651858.CD013550.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000150445","article-title":"Inflammatory markers in the tears of patients with ocular surface disease","volume":"40","author":"Acera","year":"2008","journal-title":"Ophthalmic Research"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/NDT.S81515","article-title":"High prevalence of sleep and mood disorders in dry eye patients: survey of 1,000 eye clinic visitors","volume":"11","author":"Ayaki","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"2","key":"10.1002\/14651858.CD013550.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","article-title":"Dry eye disease: impact on quality of life and vision","volume":"1","author":"Uchino","year":"2013","journal-title":"Current Ophthalmology Reports"},{"issue":"6","key":"10.1002\/14651858.CD013550.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"e0199131","DOI":"10.1371\/journal.pone.0199131","article-title":"Association between dry eye symptoms and suicidal ideation in a Korean adult population","volume":"13","author":"Um","year":"2018","journal-title":"PloS One"},{"issue":"3","key":"10.1002\/14651858.CD013550.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/ICO.0000000000001042","article-title":"Reversibility of gland dropout and significance of eyelid hygiene treatment in meibomian gland dysfunction","volume":"36","author":"Yin","year":"2017","journal-title":"Cornea"},{"issue":"4","key":"10.1002\/14651858.CD013550.pub3-BIB0021|cit21","first-page":"407\u201316","article-title":"Corticosteroid-induced glaucoma: a review of the literature","volume":"20","author":"Kersey","year":"2005","journal-title":"Eye"},{"issue":"2","key":"10.1002\/14651858.CD013550.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1444-0938.2002.tb03011.x","article-title":"What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts","volume":"85","author":"Jobling","year":"2002","journal-title":"Clinical & Experimental Optometry"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","article-title":"Locally administered ocular corticosteroids: benefits and risks","volume":"25","author":"McGhee","year":"2002","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40662-017-0072-z","article-title":"Topical tacrolimus in anterior segment inflammatory disorders","volume":"4","author":"Shoughy","year":"2017","journal-title":"Eye and Vision"},{"issue":"5","key":"10.1002\/14651858.CD013550.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical review: topical ophthalmic use of cyclosporin A","volume":"18","author":"Utine","year":"2010","journal-title":"Ocular Immunology and Inflammation"},{"issue":"2-3","key":"10.1002\/14651858.CD013550.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/OED.S16067","article-title":"Safety and efficacy of cyclosporine in the treatment of chronic dry eye","volume":"6","author":"Schultz","year":"2014","journal-title":"Ophthalmology and Eye Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013550.pub3-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005556.pub2","article-title":"Interventions for chronic blepharitis","author":"Lindsley","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12955-018-0839-5","article-title":"Development and evaluation of a measure of patient-reported symptoms of blepharitis","volume":"16","author":"Hosseini","year":"2018","journal-title":"Health and Quality of Life Outcomes"},{"issue":"11","key":"10.1002\/14651858.CD013550.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/ICO.0b013e3182a02e0e","article-title":"Assessment of signs of anterior blepharitis using standardized color photographs","volume":"32","author":"Bunya","year":"2013","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0031|cit31","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews https:\/\/community.cochrane.org\/mecir-manual August 2023"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD013550.pub3-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013550","article-title":"Topical immunosuppressants for blepharitis in adults","author":"Kam","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0034|cit34","first-page":"615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"JAMA Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD013550.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.1988.01060130353019","article-title":"Lens opacities classification system","volume":"106","author":"Leske","year":"1988","journal-title":"Archives of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD013550.pub3-BIB0036|cit36","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0037|cit37","unstructured":"Covidence Veritas Health Innovation 2024"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0039|cit39","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0040|cit40","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0041|cit41","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0042|cit42","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0043|cit43","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0044|cit44","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD013550.pub3-BIB0045|cit45","first-page":"112-8","article-title":"Comparative study of the efficacy of different treatment options in patients with chronic blepharitis","volume":"90","author":"Arrua","year":"2015","journal-title":"Archivos de la Sociedad Espanola de Oftalmologia"},{"issue":"2","key":"10.1002\/14651858.CD013550.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"267-74","DOI":"10.3109\/09273948.2015.1115879","article-title":"Loteprednol etabonate 0.5%\/tobramycin 0.3% compared with dexamethasone 0.1%\/tobramycin 0.3% for the treatment of blepharitis","volume":"25","author":"Comstock","year":"2017","journal-title":"Ocular Immunology and Inflammation"},{"issue":"15","key":"10.1002\/14651858.CD013550.pub3-BIB0047|cit47","first-page":"99","article-title":"Zylet (loteprednol etabonate 0.5%\/tobramycin 0.3%) compared with tobradex (dexamethasone 0.1%\/tobramycin 0.3%) for the treatment of lid inflammation in two populations","volume":"54","author":"Comstock","year":"2013","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0048|cit48","unstructured":"Zylet vs Tobradex in blepharokeratoconjunctivitis clinicaltrials.gov\/show\/NCT00447577"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0049|cit49","unstructured":"The clinical research of safety and effectiveness of tobrdex (0.3% and 0.1% tobramycin dexamethasone ophthalmic suspension) as control, Zylet (0.5% loteprednol and 0.3% tobramycin ophthalmic suspension) treatment blepharo-keratoconjunctivitis www.chictr.org.cn\/showproj.aspx?proj=24036"},{"issue":"7","key":"10.1002\/14651858.CD013550.pub3-BIB0050|cit50","first-page":"4867","article-title":"Zylet (loteprednol etabonate 0.5%\/tobramycin 0.3%) compared with Tobradex (dexamethasone 0.1%\/tobramycin 0.3%) for the treatment of blepharitis in a large international population","volume":"56","author":"Comstock","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0051|cit51","unstructured":"Loteprednol and tobramycin versus tobramycin and dexamethasone, in the treatment of blepharokeratoconjunctivitis clinicaltrials.gov\/show\/NCT01028027"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1185\/030079908X253898","article-title":"Comparison of the safety and efficacy of loteprednol 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis","volume":"24","author":"White","year":"2008","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2147\/OPTH.S110739","article-title":"A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin-0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis","volume":"10","author":"Hosseini","year":"2016","journal-title":"Clinical Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD013550.pub3-BIB0054|cit54","first-page":"1459","article-title":"Clinical response to treatment with topical ocular 0.1% dexamethasone in DuraSite\u00ae in subjects with blepharitis","volume":"55","author":"Hosseini","year":"2014","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD013550.pub3-BIB0055|cit55","first-page":"3058","article-title":"A phase 3 clinical study to evaluate the efficacy and safety of fixed combination of azithromycin and dexamethasone in Durasite, and dexamethasone alone in Durasite in the treatment of blepharitis","volume":"56","author":"Hosseini","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0056|cit56","unstructured":"Efficacy and safety study of a steroid\/antibiotic combination eyedrop to treat non-bacterial blepharitis (DOUBle) clinicaltrials.gov\/ct2\/show\/NCT01408082"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0057|cit57","first-page":"2225-34","article-title":"A phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis","volume":"7","author":"Hosseini","year":"2013","journal-title":"Clinical Ophthalmology"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0058|cit58","unstructured":"Efficacy of Zylet vs Lotemax for the treatment of ocular surface inflammation\/MGD\/blepharitis (ZvL) clinicaltrials.gov\/show\/NCT01456780"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0059|cit59","unstructured":"Comparative study to evaluate ISV-305 compared to vehicle in blepharitis subjects clinicaltrials.gov\/show\/NCT01543490"},{"issue":"12","key":"10.1002\/14651858.CD013550.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1386-93","DOI":"10.1097\/ICO.0b013e31823cc098","article-title":"A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction","volume":"31","author":"Prabhasawat","year":"2012","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0061|cit61","unstructured":"Efficacy of 0.05% cyclosporine ophthalmic emulsion compared with tear in meibomian gland dysfunction clinicaltrials.gov\/ct2\/show\/NCT00705510"},{"issue":"11","key":"10.1002\/14651858.CD013550.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1440-4","DOI":"10.1080\/02713683.2017.1339805","article-title":"Tacrolimus ointment for refractory posterior blepharitis","volume":"42","author":"Sakassegawa-Naves","year":"2017","journal-title":"Current Eye Research"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0063|cit63","unstructured":"Treatment of dry eye using 0.03% tacrolimus eye drops clinicaltrials.gov\/show\/NCT01850979"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0064|cit64","first-page":"171-8","article-title":"Evaluation of clinical efficacy and safety of tobramycin\/dexamethasone ophthalmic suspension 0.3%\/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis\/blepharoconjunctivitis","volume":"27","author":"Cockrum","year":"2011","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0065|cit65","unstructured":"A study to evaluate the clinical efficacy and safety of Tobradex\u00ae ST compared to Azasite\u00ae in the treatment of subjects with moderate to severe chronic blepharitis clinicaltrials.gov\/show\/NCT01102244"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0066|cit66","first-page":"16-21","article-title":"Effects of tobramycin dexamethasone eye ointment for blepharitis: multi-center clinical trial","volume":"49","author":"Yan","year":"2013","journal-title":"Chinese Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD013550.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"171-5","DOI":"10.1097\/01.ico.0000176611.88579.0a","article-title":"Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction","volume":"25","author":"Perry","year":"2006","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0068|cit68","unstructured":"Perry HD Doshi S Donnenfeld ED Biser SA Bloom AH Double masked randomized controlled study evaluating topical 0.05% cyclosporine A in the treatment of meibomian gland dysfunction (posterior blepharitis) Investigative Ophthalmology & Visual Science 2003 44 13 1395"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"47-53","DOI":"10.1089\/jop.2006.22.47","article-title":"Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis","volume":"22","author":"Rubin","year":"2006","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"13","key":"10.1002\/14651858.CD013550.pub3-BIB0070|cit70","first-page":"2662","article-title":"Comparison of the efficacy of topical cyclosporine 0.05% compared with tobradex for the treatment of posterior blepharitis","volume":"46","author":"Rao","year":"2005","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD013550.pub3-BIB0071|cit71","first-page":"1227","article-title":"Comparison of the efficacy of topical cyclosporine vs topical tacrolimus over 6 months in patients of meibomian gland dysfunction (MGD)","volume":"14","author":"Singh","year":"2023","journal-title":"Journal of Cardiovascular Disease Research"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0072|cit72","unstructured":"Open Science Framework Data set for: topical immunosuppressants for blepharitis in adults (review) osf.io\/pfy3z\/"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"3467620","DOI":"10.1155\/2021\/3467620","article-title":"Topical steroids and antibiotics for adult blepharokeratoconjunctivitis (BKC): a meta-analysis of randomized clinical trials","volume":"2021","author":"Zhao","year":"2021","journal-title":"Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013550.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2147\/OPTH.S181811","article-title":"Eye drop emulsion containing 0.1% cyclosporin (1 mg\/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy","volume":"13","author":"Nebbioso","year":"2019","journal-title":"Clinical Ophthalmology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013550.pub3-BIB0075|cit75","first-page":"AB347","article-title":"Treatment of persistent blepharitis and keratoconjunctivitis with intraocular and topical use of tacrolimus 0.03% ointment","volume":"137","author":"Syringos","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013550.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","article-title":"Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis","volume":"89","author":"Pucci","year":"2002","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013550.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/tjo.TJO-D-22-00140","article-title":"Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen","volume":"13","author":"Chan","year":"2023","journal-title":"Taiwan Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD013550.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5935\/0004-2749.20170038","article-title":"Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial","volume":"80","author":"M\u00fcller","year":"2017","journal-title":"Arquivos Brasileiros de Oftalmologia"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:32:36Z","timestamp":1788402756000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013550.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":78,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013550.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}